ライフサイエンスコーパス: muscarinic

1 lar agonists unrelated either to 28 or known muscarinics.

2 in receptor 2), CHRM2 (cholinergic receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family pe

3 QTLs identified Chrm2 (cholinergic receptor, muscarinic 2, cardiac) as a candidate susceptibility gen

4 Among multiple actions of clozapine, muscarinic acetylcholine (ACh) activation markedly reduc

5 Gq -coupled M1-type muscarinic acetylcholine (ACh) receptors (mAChRs) mediat

6 ABSTRACT: Gq -coupled M1-type muscarinic acetylcholine (ACh) receptors (mAChRs) mediat

7 eir interactions were studied with the human muscarinic acetylcholine M1-receptor (hM1) with respect

8 rs, including protease activated receptor 1, muscarinic acetylcholine M3, and histamine H1 receptors,

9 itive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (M1 mAChR) are a promi

10 sed biosensor to detect activation of the M1 muscarinic acetylcholine receptor (M1 mAChR) in vitro an

11 acetylcholine receptors, particularly the M1 muscarinic acetylcholine receptor (M1 mAChR), which was

12 Galphaq-coupled receptors, including the M1 muscarinic acetylcholine receptor (M1R), and opposes the

13 The M2 muscarinic acetylcholine receptor (M2R) was found to exh

14 n and lung function regulated through the M3-muscarinic acetylcholine receptor (M3-mAChR).

15 (SMG), production of antinuclear and anti-M3 muscarinic acetylcholine receptor (M3R) autoantibodies a

16 ation of vestibular afferents is mediated by muscarinic acetylcholine receptor (mAChR) activation and

17 Muscarinic acetylcholine receptor (mAChR) activation in

18 Nanoinjections of the muscarinic acetylcholine receptor (mAChR) agonist, oxotr

19 Muscarinic acetylcholine receptor (mAChR) blockade by sc

20 pe-selective allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been desc

21 t deficits in signaling of the M1 subtype of muscarinic acetylcholine receptor (mAChR) in the prefron

22 Here, the extracellular vestibule of the M2 muscarinic acetylcholine receptor (mAChR) is targeted fo

23 Novel bitopic hybrids, based on the M1/M4 muscarinic acetylcholine receptor (mAChR) orthosteric ag

24 77-LH-28-1 are selective agonists of the M1 muscarinic acetylcholine receptor (mAChR) that may gain

25 Selective activation of the M1 muscarinic acetylcholine receptor (mAChR) via a positive

26 , we find that the Chrm4 transcript encoding muscarinic acetylcholine receptor 4 (M4) is excessively

27 nergic, dopaminergic D3 and D4 receptors and muscarinic acetylcholine receptor 4, the receptor tyrosi

28 Disruption of NAc muscarinic acetylcholine receptor activity attenuated, w

29 Following treatment with the muscarinic acetylcholine receptor antagonist biperiden,

30 Scopolamine (hyoscine) is a muscarinic acetylcholine receptor antagonist that has tr

31 demonstrate that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces r

32 ve revealed that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces r

33 waves, MC calcium transients were blocked by muscarinic acetylcholine receptor antagonists, whereas d

34 structurally and physicochemically distinct muscarinic acetylcholine receptor antagonists.

35 CRT attenuated the increased M2 subtype of muscarinic acetylcholine receptor expression and Galphai

36 The patches are matched to a pattern of M2 muscarinic acetylcholine receptor expression at fixed lo

37 Galphai coupling and enhanced M3 subtype of muscarinic acetylcholine receptor expression in associat

38 mine (NMS) bind to the binding pocket of the muscarinic acetylcholine receptor formed by transmembran

39 The muscarinic acetylcholine receptor is an important modula

40 Human acini preferentially expressed the muscarinic acetylcholine receptor M3 and maintained phys

41 ed inflammatory cytokines and decreased M3R (Muscarinic Acetylcholine receptor M3) and AQP5 (Aquapori

42 report that activation of the M4 subtype of muscarinic acetylcholine receptor reduces transmission a

43 tractile GPCRs, but selectively inhibited M3 muscarinic acetylcholine receptor signaling ( approximat

44 otype previously used for the preparation of muscarinic acetylcholine receptor subtype 1 positive all

45 ubstantia nigra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppo

46 We found that the muscarinic acetylcholine receptor subtype M3 (M3R) inter

47 gG reactivity in patients with PV toward the muscarinic acetylcholine receptor subtypes 3, 4, and 5 a

48 Herein we address these topics for the M1 muscarinic acetylcholine receptor, a key molecular targe

49 amine receptors, 5-HT (serotonin) receptors, muscarinic acetylcholine receptor, and adrenergic recept

50 Among these, we identified CHRM3, a M3R muscarinic acetylcholine receptor, as being restricted t

51 protein-coupled receptors, including the M3 muscarinic acetylcholine receptor, can form homo-oligome

52 through an acetylcholine-gated channel and a muscarinic acetylcholine receptor, respectively.

53 tion of Gq-coupled receptors, such as the m1 muscarinic acetylcholine receptor, suppresses the M-curr

54 CIH-induced HIF-alpha isoform imbalance via muscarinic acetylcholine receptor-mediated Ca(2+) influx

55 beta2 adrenergic receptor (hbeta2AR) and M2 muscarinic acetylcholine receptor.

56 an be recapitulated with blockade of M1-type muscarinic acetylcholine receptors (M1-AChR); however, t

57 consistent with beta-arrestin binding to M1 muscarinic acetylcholine receptors (M1Rs) in two differe

58 We previously reported that type 3 muscarinic acetylcholine receptors (M3-Rs) physically in

59 cotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs) are expresse

60 y transmission mediated, for example, by the muscarinic acetylcholine receptors (mAChRs) in relevant

61 cholinergic innervation from the septum, and muscarinic acetylcholine receptors (mAChRs) share some s

62 (123)I-iododexetimide is used for imaging muscarinic acetylcholine receptors (mAchRs).

63 receptors and allosterically interacts with muscarinic acetylcholine receptors (mAChRs).

64 ces, we show that endogenous Galphaq-coupled muscarinic acetylcholine receptors activate PKA.

65 ese results propose a new mechanism by which muscarinic acetylcholine receptors affect cognition and

66 is implicated in reward, whereas blockade of muscarinic acetylcholine receptors by scopolamine suppre

67 The drug scopolamine was used to block muscarinic acetylcholine receptors involved in working m

68 The M2 subtype of muscarinic acetylcholine receptors was upregulated in hu

69 lternative strategy is to selectively target muscarinic acetylcholine receptors, particularly the M1

70 diolabeled species from all five subtypes of muscarinic acetylcholine receptors, suggesting allosteri

71 y changes in glycolysis and by activation of muscarinic acetylcholine receptors.

72 phenotype can be rescued by an antagonist of muscarinic acetylcholine receptors.

73 ergic G protein-coupled receptors, including muscarinic acetylcholine receptors.

74 y acetylcholine acting on both nicotinic and muscarinic acetylcholine receptors.

75 No difference in muscarinic acetylcholine type 2 receptor expression was

76 alpha-7 nicotinic acetylcholine receptor and muscarinic acetylcholine type 2 receptor expression, as

77 inic acetylcholine receptor) and muscarinic (muscarinic acetylcholine type 2 receptor) receptors, and

78 gonists, but not the aGPCR GPR110/ADGRF1, M3 muscarinic acetylcholine, or beta2 adrenergic GPCRs.

79 tropine, indicating that it requires ACh and muscarinic ACh receptor (mAChR) activation.

80 (nAChR)-mediated depolarizing potentials and muscarinic ACh receptor (mAChR)-mediated hyperpolarizing

81 However, it remains controversial how muscarinic ACh receptors (mAChRs) modulate striatal DA r

82 ntiated whisker-evoked CBF responses through muscarinic ACh receptors and concurrently facilitated ne

83 esence of a conserved circuit, activation of muscarinic ACh receptors revealed marked differences in

84 Sensory neurons from mice lacking the muscarinic ACh type 1 receptor (M1R) exhibited enhanced

85 e AOB were excited, MOB GCs exhibited a dual muscarinic action in the form of a hyperpolarization and

86 Acinar cell responses to the muscarinic agonist carbachol (CCh) and the bile acid tau

87 The muscarinic agonist carbachol induced pronounced transien

88 tion upon pharmacological treatment with the muscarinic agonist carbachol.

89 al rat ventricular myocytes treated with the muscarinic agonist carbachol.

90 in electroencephalograms, SE induced by the muscarinic agonist pilocarpine in mice is preceded by a

91 Muscarinic agonist treatment of hOPCs resulted in a spec

92 nd is classified as either a full or partial muscarinic agonist.

93 timulating mouse-eye pupil constriction than muscarinic agonists oxotremorin-M (Oxo-M) or carbachol (

94 by reduced insulin secretion in response to muscarinic agonists, combined with increased peripheral

95 , whereas FFA2 activation stimulated DBS via muscarinic and 5-HT4 receptor activation.

96 FA2 activation induces HCO3(-) secretion via muscarinic and 5-HT4 receptor activation.

97 ge can be evoked with combined activation of muscarinic and kainate receptors in different subregions

98 s to treat airway disease include the use of muscarinic and leukotriene receptor antagonists; however

99 gonal band of Broca (HDB) and expresses both muscarinic and nicotinic acetylcholine (ACh) receptors.

100 nse due to the combinatorial effects of both muscarinic and nicotinic activation.

101 Muscarinic and nicotinic cholinergic receptors both cont

102 ulation of cue-evoked dopamine release, with muscarinic and nicotinic receptor antagonists causing su

103 arbamylcholine on VFT that depends upon both muscarinic and nicotinic receptor stimulation, where the

104 effect of CCh on VFT that depends upon both muscarinic and nicotinic receptor stimulation, where the

105 ic inputs as well as the contribution of the muscarinic and nicotinic receptors on SSA.

106 ng and flow cytometry, and the expression of muscarinic and nicotinic receptors was evaluated by flow

107 Activation of the muscarinic and purinergic receptors by agonists shifted

108 l and combined pharmacological inhibition of muscarinic and/or beta-adrenergic receptors.

109 haled dual-pharmacology compounds, combining muscarinic antagonism and beta2-agonism (MABA) in a sing

110 on selectivity measures were also reduced by muscarinic antagonism.

111 eta2-agonist (indacaterol) and a long-acting muscarinic antagonist (glycopyrrolate), compared with it

112 s an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatme

113 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy

114 ibe the subsequent lead optimization of both muscarinic antagonist and beta2 agonist activities, thro

115 ntagonists would worsen pathophysiology, the muscarinic antagonist atropine reduced IIS frequency.

116 rsus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacerbation preve

117 Finally, we designed a muscarinic antagonist DART in one iteration, demonstrati

118 -daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50

119 (ICS) (n = 1097), 5 RCTs of the long-acting muscarinic antagonist tiotropium (n = 4592), and 6 RCTs

120 is setting occupancy of the receptors with a muscarinic antagonist was without detectable effect on a

121 roid, long-acting beta2 agonist, long-acting muscarinic antagonist, and leukotriene receptor antagoni

122 , long-acting beta2-agonist, and long-acting muscarinic antagonist, several of which are now in devel

123 er controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological

124 -adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reduction

125 All muscarinic antagonists currently used as bronchodilating

126 Therefore, solifenacin and other selective muscarinic antagonists represent new adjunct approaches

127 They were prevented by the M1-preferring muscarinic antagonists, telenzepine, pirenzepine, and tr

128 cting bronchodilators, including long-acting muscarinic antagonists, to reduce hyperinflation.

129 sal with acetylcholinesterase inhibitors and muscarinic anticholinergics in these patients.

130 The effect of CCh on VFT was abolished by a muscarinic (atropine, 0.1 mumol l(-1) , n = 6) or a nico

131 n of GABA agonists was mimicked by intra-LHb muscarinic cholinergic (mACh) antagonist injection, and

132 While muscarinic cholinergic blockade prevented the VNS-induce

133 KEY POINTS: A tonically active, muscarinic cholinergic inhibition of rostral raphe palli

134 The RVLM is not the sole source of the muscarinic cholinergic input to rRPa.

135 Importantly, we document increased muscarinic cholinergic receptor expression in Alexander

136 In pancreatic beta cells, muscarinic cholinergic receptor M3 (M3R) stimulates gluc

137 ested that its toxic effects may involve the muscarinic cholinergic receptors (mAChRs).

138 d natural compounds, and found that reducing muscarinic cholinergic signaling ameliorated clinical sy

139 its, glycopyrrolate, we confirm the role for muscarinic cholinergic signaling in pathogenesis using a

140 We further demonstrate that muscarinic cholinergic signaling works through downstrea

141 dicates that T5 expresses both nicotinic and muscarinic cholinoceptors, qualifying T5 to receive chol

142 early intervention with cholinergic receptor muscarinic (ChRM)-3 blocker reversed the progression of

143 hic pain rats due to a severe reduction of a muscarinic depolarizing current and M1 receptor internal

144 was illustrated by the synthesis of the anti-muscarinic drug, fesoterodine.

145 pounds, but not cannabinoid, neurotensin, or muscarinic drugs.

146 manipulations reveal that the enhancement of muscarinic excitation in the healthy adult PFC arises vi

147 k-in mutation T853A in mice had no effect on muscarinic force responses in isolated tracheal tissues.

148 by designer drugs) system in which a mutated muscarinic G protein-coupled receptor is activated by an

149 blation or pharmacological inhibition of the muscarinic-gated K(+) channel (IKACh) could rescue SSS a

150 to investigate structural dynamics of the M2 muscarinic GPCR that is bound by the full agonist iperox

151 ion binding on dynamic activation of the M3 muscarinic GPCR through long-timescale accelerated molec

152 nfirming the existence of a tonic inhibitory muscarinic influence on cardiac inotropy.

153 confirm the existence of a tonic inhibitory muscarinic influence on LV contractility.

154 ing firing above approximately 6-8 Hz, these muscarinic IPSPs lost their efficacy because stimulation

155 ght-induced activation of BFc axons elicited muscarinic IPSPs.

156 mpus of mice following administration of the muscarinic ligands xanomeline and 1-(4-methoxybenzyl)-4-

157 e indicative of a tetramer and unaffected by muscarinic ligands; those of eGFP-Gi1 were indicative of

158 ic AMPA, NMDA and kainate, GABAergic GABAA , muscarinic M1 , M2 and nicotinic acetylcholine (nACh; al

159 istamine H1 and H2, melanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and seroton

160 Stimulation of the cortical muscarinic M1 receptor (CHRM1) is proposed as a treatmen

161 The muscarinic M1 receptor (M1R) is highly involved in cogni

162 ent data demonstrated that activation of the muscarinic M1 receptor by a subtype-selective positive a

163 s expressing some 50 molecules.mum(-2) human muscarinic M1 receptor identified a approximately 75:25

164 In support, immunohistochemistry revealed muscarinic M1 receptor, CaV3.2, and KV7.2/7.3 subunit lo

165 Activation of muscarinic M1 receptors (M1-Rs) caused robust and revers

166 Clozapine's potent antagonism of muscarinic M1 receptors is thought to worsen working mem

167 It is hypothesized that selective muscarinic M1 subtype activation could be a strategy to

168 Muscarinic M1-M5 acetylcholine receptors are G-protein-c

169 t phases of the cue detection process, while muscarinic (M1) receptor activity was preferentially inv

170 t of spontaneous receptor activity using the muscarinic M2 acetylcholine receptor as a model.

171 compounds that elicit protean agonism at the muscarinic M2 acetylcholine receptor.

172 of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explo

173 Muscarinic m2 receptors (M2Rs) are implicated in autoreg

174 ic/allosteric (i.e. dualsteric) agonists for muscarinic M2 receptors to demonstrate the existence and

175 Targeting these cortical muscarinic M2 receptors using central cholinomimetics co

176 inity choline transporter and especially the muscarinic M2 receptors, which was confirmed by Western

177 d results pertaining to its interaction with muscarinic M3 receptor (M3R).

178 mediated through the Gs-coupled modified rat muscarinic M3 receptor (rM3Ds) induced appreciable dyski

179 ignaling Gbeta5-R7 is a crucial activator of muscarinic M3 receptor-stimulated insulin secretion.

180 ctivated receptors, heterologously expressed muscarinic M3 receptors, or by direct activation of inos

181 r encoding the engineered Gi/o-coupled human muscarinic M4 designer receptor exclusively activated by

182 ivation of a G-protein-coupled receptor, the muscarinic M5R, results in DAT-mediated DA efflux throug

183 sms underlying the antipsychotic efficacy of muscarinic modulators are not well understood.

184 lpha-7 nicotinic acetylcholine receptor) and muscarinic (muscarinic acetylcholine type 2 receptor) re

185 , cerebrum, plasma cholinesterases; cerebrum muscarinic, nicotinic receptors).

186 r this was dependent on NO generation and/or muscarinic/nicotinic receptor stimulation.

187 was without detectable effect on any of the muscarinic oligomers.

188 rgic side effects observed with nonselective muscarinic orthosteric agonists.

189 excellent model for testing the efficacy of muscarinic pharmacological entities.

190 lidal MSN activity via a Gq-coupled human M3 muscarinic receptor (hM3Dq), a type of designer receptor

191 Using the activatory Gq-coupled human M3 muscarinic receptor (hM3Dq), we found that chemogenetic

192 ized the oligomeric status of eGFP-tagged M2 muscarinic receptor (M2R) and Gi1 by single-particle pho

193 -2 regulates expression of the C. elegans M2 muscarinic receptor (m2R) ortholog, GAR-2.

194 eceptor that activates KACh channels, the M2 muscarinic receptor (M2R).

195 l subunits [Cacna1c and Cacnb2], cholinergic muscarinic receptor 4 [Chrm4)], dopamine receptor D2 [Dr

196 receptor type contributions, we find that m2 muscarinic receptor activation increases glomerular sens

197 Muscarinic receptor activation resulting from ACh releas

198 omponents of the signalling pathway coupling muscarinic receptor activation to changes in chemorecept

199 Although PV BCs were also excited by muscarinic receptor activation, they more frequently res

200 trinsic glial properties related to enhanced muscarinic receptor activation.

201 ter the stimulation paradigm and were due to muscarinic receptor activation.

202 d theta oscillations, and both nicotinic and muscarinic receptor activity contributed to this process

203 RTN chemoreceptors to ACh was mimicked by a muscarinic receptor agonist (oxotremorine; 1 mum), and b

204 served more than 30 min after removal of the muscarinic receptor agonist.

205 Muscarinic receptor agonists are characterized by appare

206 currently limited to medications (e.g., the muscarinic receptor agonists pilocarpine and cevimeline)

207 salivation are limited to medications (e.g., muscarinic receptor agonists: pilocarpine and cevimeline

208 ing iontophoretic application of the general muscarinic receptor antagonist scopolamine with single-c

209 studies have suggested that the long-acting muscarinic receptor antagonist tiotropium, a drug widely

210 Here, we show that the muscarinic receptor antagonist, atropine, eliminated the

211 treatment with solifenacin, an FDA-approved muscarinic receptor antagonist, increased oligodendrocyt

212 0, 0.03, or 0.1 mg/kg, intraperitoneally), a muscarinic receptor antagonist, or mecamylamine (0, 0.75

213 haled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting b

214 rendered ineffective by either nicotinic or muscarinic receptor antagonists.

215 Here, we examined the effects of muscarinic receptor blockade on rule-related activity in

216 bdivision; 3) distinct kainate, alpha2 , and muscarinic receptor densities that rendered distinctive

217 Each subtype of the muscarinic receptor family of G protein-coupled receptor

218 The alteration of PSC muscarinic receptor functions also persists during the p

219 nt of cells expressing such mutants with the muscarinic receptor inverse agonist atropine increased c

220 The M2 muscarinic receptor is the prototypic model of allostery

221 tussis toxin or in myocytes from M2- or M1/3-muscarinic receptor knockout mice, atropine increased cA

222 , Shen et al. (2015) demonstrate that the M4 muscarinic receptor regulates striatal plasticity.

223 y and underlie the K(+) current sensitive to muscarinic receptor signaling (the M current) in sympath

224 um nitroprusside was ultimately dependent on muscarinic receptor stimulation as all effects were bloc

225 striatal cholinergic interneurons (ChIs) and muscarinic receptor subtypes (mAChRs) in the occurrence

226 Of the five muscarinic receptor subtypes, the M5 receptor is the onl

227 ating agents show high affinity for all five muscarinic receptor subtypes, thus increasing the likeli

228 Monomers and oligomers of the M2 muscarinic receptor therefore have been compared to iden

229 n's Syndrome (SS) and HCV, presence of anti- muscarinic receptor type 3 (M3R) antibodies in SS, the r

230 Here we show that muscarinic receptor type-1 (Chrm1) signaling in the hypo

231 ed monomers and tetramers of the purified M2 muscarinic receptor were compared with muscarinic recept

232 and Galpha(1)(3) coupled receptors (such as muscarinic receptor, m1, and thrombin receptor, PAR-1) a

233 orded with another cognate G protein-coupled muscarinic receptor, M1R.

234 ium-dependent vasodilatations in response to muscarinic receptor, TRPV4 (transient receptor potential

235 al proliferation and tumorigenesis in an ACh muscarinic receptor-3 (M3R)-dependent manner, in part th

236 t study, by expressing an arrestin-biased M3 muscarinic receptor-based DREADD (M3D-arr) in stable hER

237 orylation site in a region homologous to the muscarinic receptor-binding site of Tau suggests that MA

238 odulate the SCA-induced locomotor rhythm via muscarinic receptor-dependent mechanisms and that the mo

239 r cholinergic constraint that is mediated by muscarinic receptor-dependent regulation of mitochondria

240 he quaternary organization of the related M3 muscarinic receptor.

241 ta2-adrenergic receptor (beta2AR) and the M2 muscarinic receptor.

242 ayers of primary motor cortex (M1) through a muscarinic-receptor mediated mechanism, gamma oscillatio

243 1) quinone reductase 2 (QR2) expression is a muscarinic-receptor-dependent removable constraint on me

244 Activation of M2 muscarinic receptors (M2Rs) in the rat anterior basolate

245 beta-Cell M3 muscarinic receptors (M3Rs) are known to play an essenti

246 endogenous cholinergic signaling through M4 muscarinic receptors (M4Rs) promoted long-term depressio

247 electivity, has been increasingly applied to muscarinic receptors (MRs).

248 GABAA-LTP requires the activation of M1-muscarinic receptors and an increase in cytosolic Ca(2+)

249 Muscarinic receptors and beta-adrenoceptors are physiolo

250 to the efficient coupling between endogenous muscarinic receptors and GIRK channels, we found that fi

251 garding the intrinsic voltage sensitivity of muscarinic receptors and the consequences of this intrig

252 port the crystal structures of the M1 and M4 muscarinic receptors bound to the inverse agonist, tiotr

253 e et al. (2017) demonstrate that presynaptic muscarinic receptors counteract the effects of dopamine

254 Blockade of muscarinic receptors had no effect on evoked dopamine re

255 Although muscarinic receptors have been implicated in executive p

256 Blocking muscarinic receptors impairs learning for nearly all odo

257 lexander disease patients, and that blocking muscarinic receptors in Alexander disease model mice red

258 These results demonstrate that blockade of muscarinic receptors in DLPFC creates deficits in workin

259 The finding that blockade of muscarinic receptors in mPFC impaired trace conditioning

260 x behavior of oligomers is characteristic of muscarinic receptors in myocardial preparations.

261 ed M2 muscarinic receptor were compared with muscarinic receptors in sarcolemmal membranes for the ef

262 These results indicate that muscarinic receptors in striatal output neurons reliably

263 (ACh) from medial septal afferents activates muscarinic receptors on both vasoactive intestinal pepti

264 e-dependent inhibition of DA release through muscarinic receptors only in the shell, where higher act

265 Muscarinic receptors represent a promising therapeutic t

266 this notion, we find that sAHP inhibition by muscarinic receptors that increase phosphoinositide turn

267 tylcholine release at these synapses allowed muscarinic receptors to faithfully encode physiological

268 ACh then activates MAPK/ERK via muscarinic receptors to promote neurite outgrowth.

269 erved in principal neurons were dependent on muscarinic receptors type 1, engaging different intracel

270 usly shown that dendritic cells (DC) express muscarinic receptors, as well as the enzymes responsible

271 which is a known allosteric modulator of the muscarinic receptors, is also shown to be a modulator of

272 sal striatum and pharmacological blockade of muscarinic receptors, specifically postsynaptic M1 and M

273 rough distinct actions at both nicotinic and muscarinic receptors, triggers a procession of neural os

274 vasodilatations in response to activation of muscarinic receptors, TRPV4 channels or IK/SK channels w

275 Thus, during submaximal activation of muscarinic receptors, V(m) can modulate Ca(2+) entry thr

276 ral GPCRs, including beta2-adrenergic and M2 muscarinic receptors, which are commonly used as represe

277 ions (basket cells, BCs) were depolarized by muscarinic receptors.

278 that this effect is mediated exclusively by muscarinic receptors.

279 ing cholinergic system through nicotinic and muscarinic receptors.

280 This effect was mainly mediated by muscarinic receptors.

281 Solely by Synthetic Ligand (RASSL) forms of muscarinic receptors.

282 were mediated by co-activation of M1 and M3 muscarinic receptors.

283 CNQ channels and is known to be inhibited by muscarinic receptors.

284 acetylcholine, the latter occurring through muscarinic receptors.

285 uately explained solely by its antagonism at muscarinic receptors.

286 parasympathetic ACh slows the heart through muscarinic receptors.

287 c neuron in the OB, also exhibited a complex muscarinic response.

288 Thus, nerve-mediated muscarinic responses in signalling modules acting on RLC

289 defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based

290 ations were consistent with suppression of a muscarinic-sensitive K(+)-current, or M-current.

291 We have therefore identified glial muscarinic signaling as a potential therapeutic target i

292 ck-out mice experiments demonstrated that M1 muscarinic signaling is critical for cholinergic control

293 The fact that we also show that muscarinic signaling is maintained in both AD and mouse

294 Thus, enhancing hippocampal muscarinic signaling using M1 mAChR PAMs restored memory

295 itide metabolism in sympathetic neurons upon muscarinic stimulation and used the kinetic information

296 nositol 1,4,5-trisphosphate, and Ca(2+) upon muscarinic stimulation in sympathetic neurons from adult

297 We demonstrated that VPA treatment disrupts muscarinic suppression of the M-current and prevents res

298 n order to image the beta-adrenergic and the muscarinic systems.

299 tive antagonists, pirenzepine, VU0255035, or muscarinic toxin 7 (MT7) activated AMPK and overcame dia

300 y, after pharmacological manipulation of the muscarinic transmission.

301 ation of hnRNPA2/B1 mRNA by activation of M1 muscarinic type receptors.